Theriva BiologicsTOVX
About: Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Employees: 22
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
35.22% less ownership
Funds ownership: 36.46% [Q3] → 1.24% (-35.22%) [Q4]
47% less funds holding
Funds holding: 17 [Q3] → 9 (-8) [Q4]
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
91% less capital invested
Capital invested by funds: $679K [Q3] → $60K (-$619K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for TOVX.
Financial journalist opinion









